肺癌中针对源自膜联蛋白A1（ANXA1）和叉头框蛋白P3（FOXP3）的线性肽抗原的循环抗体
Circulating Antibodies to Linear Peptide Antigens Derived from ANXA1 and FOXP3 in Lung Cancer.
作者信息
Wang Weili, Zhong Wen, Chen Cairen, Meng Qingyong, Wei Jun
机构信息
Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, IN, U.S.A.
Department of Radiation Oncology, the Fourth Affiliated Hospital, China Medical University, Shenyang, P.R. China.
出版信息
Anticancer Res. 2017 Jun;37(6):3151-3155. doi: 10.21873/anticanres.11673.
BACKGROUND
Our previous studies revealed that concentrations of circulating antibodies to annexin A1 (ANXA1) and forkhead-box P3 (FOXP3) increased significantly in patients with non-small cell lung cancer (NSCLC). This study was thus undertaken to replicate our initial findings with different sample sets.
PATIENTS AND METHODS
Antibodies were tested in 108 patients with NSCLC and 216 controls, who were divided into the discovery (49 vs. 108) and validation (60 vs. 108) group based on the time of enrolment.
RESULTS
Analysis of the discovery group showed a significant increase in circulating anti-ANXA1 IgG levels in the patient group compared with the control group (p=0.005) but the validation group simply exhibited a trend toward an increase in IgG levels in NSCLC (p=0.238), generating a combined p-value of 0.009.
CONCLUSION
The findings of this study support the notion that circulating IgG antibodies to ANXA1 could be used as a biomarker for early diagnosis of NSCLC but failed to replicate such findings for FOXP3.
背景
我们之前的研究表明，非小细胞肺癌（NSCLC）患者循环中膜联蛋白A1（ANXA1）和叉头框蛋白P3（FOXP3）抗体浓度显著升高。因此，本研究旨在使用不同样本集重复我们最初的研究结果。
患者和方法
对108例NSCLC患者和216例对照者进行抗体检测，根据入组时间将其分为发现组（49例对108例）和验证组（60例对108例）。
结果
发现组分析显示，与对照组相比，患者组循环抗ANXA1 IgG水平显著升高（p=0.005），但验证组仅显示NSCLC患者IgG水平有升高趋势（p=0.238），合并p值为0.009。
结论
本研究结果支持以下观点，即循环中抗ANXA1 IgG抗体可作为NSCLC早期诊断的生物标志物，但未能重复FOXP3的相关研究结果。
Zotero 插件